CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 vs MK-677: Research Comparison Guide

Real Peptides Research TeamEditorial

Updated March 30, 20268 min read

56 WORDS

Short answer

The most common error in CJC-1295 vs MK-677 procurement isn't picking the wrong compound. It's assuming the two are interchangeable because both elevate growth hormone. One is an injectable peptide acting on the growth hormone releasing hormone receptor. The other is an orally active non-peptide acting on the ghrelin receptor. Different chemistry, different kinetics, different handling.

Key takeaways

CJC-1295 is a GHRH receptor analog and MK-677 is a GHS-R1a ghrelin receptor agonist, so the two compounds are complementary mechanisms rather than substitutes.
CJC-1295 without DAC has a short half-life producing pulsatile growth hormone release, while the DAC-modified version binds albumin to sustain elevation for days.
MK-677 is the only one of the two that is orally active, because it is a non-peptide small molecule rather than a peptide chain.
Single trough IGF-1 sampling structurally disadvantages short-acting GHRH analogs in any CJC-1295 vs MK-677 comparison; serial sampling is required for a fair readout.
Published MK-677 research reports increased fat-free mass alongside findings including increased appetite, transient edema, and altered insulin sensitivity.
Neither compound is FDA-approved, and both are supplied for laboratory research use only.

Our team supplies research-grade material to labs running secretagogue comparisons, and the questions we field most often concern peptide stability, purity documentation, and measurement windows rather than raw potency. That ordering is the correct one.

CJC-1295 vs MK-677: what is the difference?

CJC-1295 is a synthetic GHRH (growth hormone releasing hormone) analog that stimulates pituitary somatotrophs directly. MK-677, also called ibutamoren, is a non-peptide ghrelin receptor agonist studied orally. Research reports both raise growth hormone and IGF-1, but through separate receptors, with markedly different half-lives and laboratory handling requirements. Both are research use only.

The framing that trips most buyers up is the idea that one compound is simply stronger than the other. Published work measures them on different endpoints, one on pulsatile growth hormone output and the other largely on sustained IGF-1 elevation, so a head-to-head potency ranking is mostly an artifact of study design. This brief covers receptor mechanism, half-life and its effect on your assay window, and what to verify on a certificate of analysis before either compound enters a protocol.

Two receptors, one hormonal axis

CJC-1295 and MK-677 arrive at growth hormone release through completely separate doors. CJC-1295 is a modified analog of GRF (1-29), the biologically active fragment of endogenous GHRH, with amino acid substitutions that resist degradation by DPP-4 (dipeptidyl peptidase-4), the enzyme that clears native GHRH from circulation within minutes. It binds the GHRH receptor on somatotroph cells of the anterior pituitary, which triggers cAMP signaling and growth hormone secretion. The DAC variant carries a drug affinity complex, a linker that binds serum albumin and extends circulation time dramatically; the no-DAC form, often catalogued as modified GRF (1-29), has no such linker.

MK-677 binds GHS-R1a, the growth hormone secretagogue receptor that endogenous ghrelin activates. It is not a peptide at all. That single structural fact explains its oral bioavailability and why the published literature on ibutamoren describes once-daily oral administration in study subjects while GHRH analogs appear in subcutaneous injection studies.

Here is the part most comparison pages skip: neither mechanism overrides somatostatin, the inhibitory hormone that gates pituitary output. Both compounds work within an intact feedback loop, which is exactly why the literature reports amplified natural secretion patterns rather than unlimited elevation. We've seen more study designs fail on that misunderstanding than on any sourcing problem.

Half-life, pulsatility, and the measurement window

The divergence that actually matters in CJC-1295 vs MK-677 work is temporal, not pharmacological. CJC-1295 without DAC has a short circulating half-life measured in tens of minutes, producing a sharp, time-limited growth hormone pulse. The DAC-modified version, through albumin binding, has been reported in published clinical pharmacology work to sustain elevated growth hormone and IGF-1 concentrations for days after a single administration. MK-677 sits between them in practice: studies describe a pharmacokinetic profile compatible with once-daily oral dosing and sustained elevation of IGF-1 across weeks of administration.

Here's the practical consequence, and it's the single most expensive mistake we see in secretagogue research. A short-acting GHRH analog produces a pulse that a single timed serum draw can miss entirely. If a lab compares CJC-1295 vs MK-677 using one trough IGF-1 measurement per subject per week, the design is structurally biased toward the compound with the flatter curve. The no-DAC peptide isn't underperforming in that scenario. It's being measured wrong. Serial sampling or area-under-the-curve analysis is the only way to capture pulsatile output honestly.

The safety literature also diverges. Published research on MK-677, including work in older adults, reports increases in fat-free mass alongside findings such as increased appetite, transient lower-extremity edema, and changes in fasting glucose and insulin sensitivity. Studies of GHRH analogs report a different adverse-event profile centred on injection-site reactions. Any CJC-1295 vs MK-677 comparison that ignores this asymmetry is incomplete.

What to verify before a compound enters a protocol

Purity documentation is where a CJC-1295 vs MK-677 purchase decision is actually won or lost. Peptides and small molecules fail differently, and the certificate of analysis should reflect that. For a lyophilised peptide such as CJC-1295, look for HPLC purity data and mass spectrometry confirming the expected molecular weight, since truncated or deamidated sequences can pass a simple appearance check while binding the GHRH receptor poorly. For a non-peptide like MK-677, identity confirmation against the compound's CAS registry number and molecular formula is the equivalent check.

Storage requirements differ just as sharply. Lyophilised peptides are handled cold, protected from light and moisture, with reconstituted solutions refrigerated and used within a limited window, because hydrolysis of the peptide backbone is irreversible and invisible. A small-molecule powder is generally the more forgiving material in shipping and on the shelf. Cold chain integrity matters far more on the peptide side of this comparison.

Real Peptides produces every catalog compound through small-batch synthesis with exact amino acid sequencing, and publishes batch certificates of analysis so a purchasing decision rests on documentation rather than a supplier's description. Our team has reviewed hundreds of third-party certificates across this category. The pattern is consistent: suppliers who won't produce a batch-specific COA on request usually can't.

CJC-1295 vs MK-677: side-by-side research comparison

This table summarises the structural, kinetic, and handling differences that determine which compound fits a given research question. Use it as a procurement filter, not a potency ranking.

Factor	CJC-1295 (no DAC)	MK-677 (Ibutamoren)	Bottom Line for the Lab
Molecular class	29-amino-acid GHRH analog, a peptide requiring reconstitution	Non-peptide small molecule, orally active in published studies	Chemistry alone dictates two different handling and stability workflows
Receptor target	GHRH receptor on anterior pituitary somatotrophs	GHS-R1a, the endogenous ghrelin receptor	Choose by pathway being interrogated, not by expected magnitude of effect
Reported duration	Short circulating half-life; produces a discrete pulse	Profile compatible with once-daily administration in study designs	Sampling schedule must match the compound or results will mislead
Published human research	Clinical pharmacology work on GHRH analogs reports growth hormone and IGF-1 elevation	Multiple controlled trials, including studies in older adults reporting IGF-1 and fat-free mass changes	MK-677 carries the larger controlled-trial literature base
Handling and stability	Cold storage of lyophilised powder; reconstituted solution is time-limited	Powder is comparatively stable under standard laboratory storage	Peptide arms of a study need documented cold chain from supplier to bench
Documentation to demand	HPLC purity plus mass spectrometry sequence confirmation	Identity confirmation against CAS number and molecular formula	No batch-specific COA means no defensible data downstream

What If: procurement and study-design scenarios

What if the lyophilised powder looks different from the last batch?

Stop, document the appearance, and check the batch certificate before reconstitution. Lyophilised peptide cake structure varies legitimately with fill volume and freeze-drying conditions, so a flatter or more fragmented cake is not automatically a quality failure. What matters is whether the batch-specific HPLC and mass spectrometry data match the expected purity and molecular weight. Visual inspection cannot detect deamidation or truncated sequences, which is precisely why documentation exists.

What if IGF-1 readings barely move in the GHRH analog arm?

Check the sampling schedule before questioning the compound. Short-acting GHRH analogs amplify existing pulsatile secretion, and a pulse can rise and fall entirely between two widely spaced draws. Sustained secretagogues like MK-677 produce a flatter curve that a trough measurement captures easily. This asymmetry is the most frequent source of misleading conclusions in CJC-1295 vs MK-677 study designs, and it is a measurement problem, not a potency problem.

What if a supplier cannot provide a batch-specific certificate?

Treat the absence of batch-level documentation as disqualifying and source elsewhere. A generic certificate showing a representative lot tells you nothing about the vial on your bench, since purity varies batch to batch with synthesis conditions and purification runs. Publicly posted, batch-matched certificates are the only verifiable link between what was synthesised and what was shipped. Any downstream data built on undocumented material is difficult to defend in review.

The unglamorous truth about secretagogue comparisons

Here's the honest answer: asking which compound is stronger is the wrong question, and the published literature won't settle it. The trials were run decades apart, in different populations, against different endpoints, by researchers asking unrelated questions. MK-677 has the deeper controlled-trial record largely because it was developed as an oral drug candidate and taken through formal clinical programs. That is a regulatory history, not a verdict on relative potency. Pick the compound whose receptor matches your research question, then build the sampling schedule around its kinetics. Everything else is marketing noise.

Researchers working across both pathways can review batch documentation for CJC-1295 no DAC and MK-677, read the broader CJC-1295 research overview, work through common CJC-1295 questions, check published certificates of analysis, or browse the full research catalog.

CJC-1295 vs MK-677 keeps getting written up as a rivalry, but the two molecules were never competitors in the literature that produced them. One came out of decades of GHRH fragment chemistry aimed at stabilising a hormone the body clears in minutes. The other came out of a search for an orally active ghrelin mimetic. The growth hormone axis is one system with several entry points, and the compound that gives a lab the cleanest signal is whichever one the experimental question was actually built around.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 is a peptide analog of growth hormone releasing hormone that binds the GHRH receptor on pituitary somatotrophs, while MK-677 is a non-peptide ghrelin receptor agonist that binds GHS-R1a. Because MK-677 is a small molecule, it is orally active in published studies, whereas CJC-1295 is a lyophilised peptide requiring reconstitution. Both are supplied for laboratory research use only.

MK-677 carries the larger controlled-trial literature, including studies in older adults reporting IGF-1 elevation and increases in fat-free mass, largely because it was advanced through formal clinical development as an oral drug candidate. GHRH analogs including CJC-1295 appear in clinical pharmacology work reporting sustained growth hormone and IGF-1 elevation, but across a smaller set of published trials. Volume of literature reflects development history, not relative potency.

The DAC, or drug affinity complex, is a linker that binds the peptide to serum albumin, dramatically extending its circulating duration; published pharmacology work reports sustained growth hormone and IGF-1 elevation for days after a single administration. Without DAC, the compound is essentially modified GRF (1-29) and clears within tens of minutes, producing a discrete pulse instead of a plateau. The two forms are not interchangeable in a study design.

Lyophilised peptides such as CJC-1295 are handled cold, kept dry, and protected from light, with reconstituted solutions refrigerated and used within a limited window because peptide backbone hydrolysis is irreversible and undetectable by visual inspection. Small-molecule powders like MK-677 are generally more tolerant of ambient conditions during shipping and storage. Cold chain integrity is the greater concern on the peptide side.

For a peptide, the certificate should include HPLC purity data and mass spectrometry confirming the expected molecular weight, which together rule out truncated or degraded sequences. For a non-peptide compound, identity confirmation against the CAS registry number and molecular formula serves the same purpose. The certificate must be batch-specific; a representative lot document tells you nothing about the vial you received.

Neither compound is an approved drug product. Both are supplied as research chemicals for laboratory investigation only, not for human or veterinary consumption. Any claim that either compound treats a condition or produces a guaranteed outcome falls outside what the research literature supports and outside what a research supplier may state.

Published trials of ibutamoren report findings including increased appetite, transient lower-extremity edema, muscle discomfort, and changes in fasting glucose and insulin sensitivity in study participants. These findings are consistent with sustained activation of the growth hormone axis. The adverse-event profile described for GHRH analogs in the literature is different in character, weighted toward injection-site reactions.

Short-acting GHRH analogs amplify pulsatile secretion, so growth hormone rises and falls within a narrow window that widely spaced sampling can miss entirely. Sustained secretagogues produce a flatter curve that a single trough draw captures easily. Serial sampling or area-under-the-curve analysis is the only fair way to compare a pulsatile compound against a sustained one.

They target separate receptors on the same hormonal axis, the GHRH receptor and GHS-R1a, so combination arms appear in mechanistic research interested in pathway interaction. Study parameters for any such design belong to the investigating institution and its review process, not to a supplier. Neither pathway overrides somatostatin, the inhibitory signal that gates pituitary output.

Pricing varies widely by compound, quantity, purity grade, and supplier, and peptide synthesis is generally the more resource-intensive process because it involves sequential amino acid coupling and purification. Small-batch peptide synthesis with full analytical verification costs more than bulk material sold without batch documentation, which is usually where unusually low prices come from. Compare the certificate before comparing the price.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA